Low-dose tissue plasminogen activator followed by planned rescue angioplasty reduces time to reperfusion for acute myocardial infarction treated at community hospitals

Japanese Circulation Journal

Volumn 65, Issue 10, 2001, Pages 901-906

  Kimura, K ^a   Tsukahara, K ^a   Usui, T ^a   Okuda, J ^a   Kitamura, Y ^a   Kosuge, M ^a   Sano, T ^a   Tohyama, S ^a   Yamanaka, O ^a   Yoshii, Y ^a   Umemura, S ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Acute myocardial infarction; Angioplasty; Reperfusion; Thrombolysis

Indexed keywords

CREATINE KINASE; MONTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REPERFUSION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; BLOOD; CLINICAL PROTOCOL; COMMUNITY HOSPITAL; FIBRINOLYTIC THERAPY; METHODOLOGY; MIDDLE AGED; STANDARD; TIME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL PROTOCOLS; CREATINE KINASE; FEMALE; HOSPITALS, COMMUNITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034761615     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.65.901     Document Type: Article

References (23)

1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients
2. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
3. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
4. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction
5. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the real world: One-year results from a nationwide French survey
6. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the second National Registry of Myocardial Infarction (NRMI-2)
7. The volume of primary angioplasty procedures and survival after acute myocardial infarction: The National Registry of Myocardial Infarction 2 investigators
8. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial
9. Efficacy of low-dose mutant tissue-type plasminogen activator followed by planned rescue percutaneous transluminal coronary angioplasty as reperfusion therapy for acute myocardial infarction
10. Combined revascularization strategy for acute myocardial infarction in patients with intracoronary thrombus: Preceding intracoronary thrombolysis and subsequent mechanical angioplasty
11. Dangers of delay of initiation of either thrombolysis or primary angioplasty in acute myocardial infarction with increasing use of primary angioplasty
12. Community practice of primary angioplasty for myocardial infarction
13. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: Comparison with native t-PA
14. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings
15. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
16. The effect of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction
17. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
18. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
19. Factors influencing the time to thrombolysis in acute myocardial infarction: Time to thrombolysis substudy on the National Registry of Myocardial Infarction-1
20. Time to therapy and salvage in myocardial infarction
21. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction
22. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) trial
23. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from TIMI 14 Trial